Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

NextCure, Inc. NXTC NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
59/100
4/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$15.00
+17.5%

NextCure, Inc. (NXTC) is a Biotechnology company in the Healthcare sector, currently trading at $12.77. It has a SharesGrow Score of 58/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is NXTC = $15 (+17.5% upside).

Valuation: NXTC trades at a trailing Price-to-Earnings (P/E) of -0.7 (S&P 500 average ~25).

Net income is $56M (loss), growing at +6.9%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $4M against $35M equity (Debt-to-Equity (D/E) ratio 0.12, conservative). Current ratio is 4.14 (strong liquidity). Debt-to-assets is 8.3%. Total assets: $50M.

Analyst outlook: 11 / 13 analysts rate NXTC as buy (85%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 75/100 (Pass), Growth 65/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 88/100 (Pass), Income ?/100 (Fail).

$15.00
▲ 17.46% Upside
Average Price Target
The 12-month price target for NextCure, Inc. is $15.00.

NXTC SharesGrow Score Overview

71/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 75/100
Valuation — P/E, PEG, Forward PEG
GROWTH 65/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 88/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NXTC

✓
VALUE Pass
75/100
NXTC trades at a trailing Price-to-Earnings (P/E) of -0.7 (S&P 500 average ~25). Forward PEG -0.04 — Peter Lynch undervalued (≤1.0). Analyst consensus target is $15, implying +17.5% from the current price $13. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✓
GROWTH Pass
65/100
NXTC: +0%/yr revenue is, +6.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet NXTC: Debt-to-Equity (D/E) ratio 0.12 (conservative), Current ratio is 4.14 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
NXTC: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
88/100
Analyst outlook: 11 / 13 analysts rate NXTC as buy (85%). Analyst consensus target is $15 (+17.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.688-15.74
Volume52.25K
Avg Volume (30D)38.05K
Market Cap$34.22M
Beta (1Y)1.58
Share Statistics
EPS (TTM)-19.65
Shares Outstanding$2.84M
IPO Date2019-05-09
Employees43
CEOMichael S. Richman
Financial Highlights & Ratios
Gross Profit$-2.19M
EBITDA$-55.43M
Net Income$-55.84M
Operating Income$-57.62M
Total Cash$41.82M
Total Debt$4.15M
Net Debt$-21.83M
Total Assets$50.18M
Price / Earnings (P/E)-0.6
Analyst Forecast
1Y Price Target$15.00
Target High$15.00
Target Low$15.00
Upside+17.5%
Rating ConsensusBuy
Analysts Covering13
Buy 85% Hold 8% Sell 8%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS65343E2072

Price Chart

Track all markets on TradingView
NXTC
NextCure, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
2.69 52WK RANGE 15.74

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.78
-0.36%
 ACHL
ACHL
Achilles Therapeutics plc
$1.48
+0.68%
 TIL
TIL
Instil Bio, Inc.
$8.44
+1.02%
 NLTX
NLTX
Neoleukin Therapeutics, Inc.
$3.49
+1.45%
 LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message